Published in J Virol on October 01, 2001
The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J Virol (2006) 1.78
A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis (2011) 1.15
Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13
Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med (2003) 1.09
Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog (2013) 1.04
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest (2013) 0.91
Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med (2004) 0.87
Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model. Front Immunol (2014) 0.86
Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection. Vet Immunol Immunopathol (2009) 0.85
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel) (2016) 0.77
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells. MBio (2016) 0.75
Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses. Mol Ther (2010) 0.75
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med (2000) 2.69
Escape of human immunodeficiency virus from immune control. Annu Rev Immunol (1997) 2.52
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS (1999) 1.87
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet (1998) 1.62
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS (1999) 1.34
Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS (2000) 1.22
HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood (2000) 1.14
HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol (1999) 0.95
Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence. Nature (1994) 0.93
Lysis of CD4+ T cells expressing HIV-1 gag peptides by gag-specific CD8+ cytotoxic T cells. Immunol Lett (1998) 0.90
Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med (1998) 0.85
Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease. J Virol (2000) 0.82
T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy. Blood (2001) 0.80
Prospective views of HIV pathology. Clues for therapeutic strategies. Adv Exp Med Biol (1995) 0.78
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol (1999) 2.76
HIV viraemia and seroconversion. Lancet (1993) 1.16
HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood (2000) 1.14
AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications. AIDS Res (1986) 1.08
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.03
Elevation of IgE in HIV-infected subjects: a marker of poor prognosis. J Allergy Clin Immunol (1992) 1.02
Tumor necrosis factor production in HIV-seropositive subjects. Relationship with lung opportunistic infections and HIV expression in alveolar macrophages. J Immunol (1991) 0.97
Glucocorticoids rescue CD4+ T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy. AIDS (1995) 0.97
Unusual pulmonary infection in a puzzling presentation of AIDS. Lancet (1985) 0.95
Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence. Nature (1994) 0.93
Evaluation of some binding parameters of hapten-antibody complexes using dextran-coated charcoal to separate the bound and free fractions. Immunochemistry (1974) 0.93
Correlation between CD4 cell counts and cellular and plasma viral load in HIV-1-seropositive individuals. AIDS (1991) 0.90
Lysis of CD4+ T cells expressing HIV-1 gag peptides by gag-specific CD8+ cytotoxic T cells. Immunol Lett (1998) 0.90
Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer (1983) 0.89
Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood (1993) 0.89
Similar replication capacities of primary human immunodeficiency virus type 1 isolates derived from a wide range of clinical sources. J Virol (1992) 0.88
HIV isolation from pulmonary cells derived from bronchoalveolar lavage. Clin Exp Immunol (1991) 0.87
Nocardia thyroiditis: unusual location of infection. J Clin Microbiol (1999) 0.86
Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients. AIDS (1993) 0.85
Studies on a new variant of the Hermansky-Pudlak syndrome: qualitative, ultrastructural, and functional abnormalities of the platelet-dense bodies associated with a phospholipase A defect. Am J Hematol (1978) 0.85
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann Oncol (1996) 0.84
Hodgkin's disease in HIV-infected intravenous drug abusers. N Engl J Med (1990) 0.84
AIDS-associated non-Hodgkin lymphoma. Lancet (1991) 0.83
Serum suppressive activity of HIV seropositive patients. Clin Exp Immunol (1988) 0.83
Chemotherapy--radiotherapy association in Hodgkin's disease, clinical stages IA, II2A: results of a prospective clinical trial with 166 patients. Cancer (1980) 0.82
Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease. J Virol (2000) 0.82
High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type 1-related diseases. J Infect Dis (1993) 0.81
Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis (1990) 0.81
Autoreactive cytotoxicity in HIV-infected individuals. Clin Exp Immunol (1990) 0.81
[Hodgkin's disease: characteristics and prognosis of forms with initial bone marrow involvement (author's transl)]. Nouv Presse Med (1981) 0.81
Clinical and biological characteristics of malignant lymphomas in HIV-infected patients. Eur J Cancer (1992) 0.80
Early identification of human immunodeficiency virus-infected asymptomatic subjects susceptible to zidovudine by quantitative viral coculture and reverse transcription-linked polymerase chain reaction. J Infect Dis (1993) 0.80
The chemotherapy--radiotherapy sequence in the management of Hodgkin's disease. Results of a clinical trial. Eur J Cancer (1979) 0.80
Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A. Adv Exp Med Biol (1995) 0.80
Enhanced dendritic cell-driven proliferation and anti-HIV activity of CD8(+) T cells by a new phenothiazine derivative, aminoperazine. J Immunol (2001) 0.80
Validity of PG E1 radioimmunoassay by using PG E1 antisera with differential binding parameters. FEBS Lett (1975) 0.80
Relationship between frequency of infectious human immunodeficiency virus type 1-harboring cells and kinetics of viral replication: a simple procedure for quantitation of infectious virus-carrying cells in blood samples. J Clin Microbiol (1992) 0.79
HLA genotypes in familial Hodgkin's disease. Excess of HLA identical affected subs. Eur J Cancer (1980) 0.79
Short-term endocrinological results after gamma knife surgery of pituitary adenomas. Stereotact Funct Neurosurg (1998) 0.79
[Hodgkin's disease associated with HIV infection: clinical characteristics and development. French registry of tumors associated with HIV infection]. Bull Cancer (1992) 0.78
[Burkitt-type lymphoma following Hodgkin's disease]. Nouv Presse Med (1980) 0.78
Enzyme immunoassay of progesterone at the picogram level using beta-galactosidase as label. Biochim Biophys Acta (1975) 0.78
Prospective views of HIV pathology. Clues for therapeutic strategies. Adv Exp Med Biol (1995) 0.78
Apoptosis and HIV disease. Nat Med (1995) 0.77
Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir (Wien) (1998) 0.77
The induction of reciprocal translocations in mouse germ cells by chemicals and ionizing radiations. I. Dose-response relationships and combined effects of bleomycin with thio-tepa and gamma-rays. Mutat Res (1988) 0.77
Mepacrine labelling test and uranaffin cytochemical reaction in human megakaryocytes. Thromb Haemost (1982) 0.77
[Acute lymphoblastic leukemia associated with blood and cerebrospinal fluid eosinophilia]. Nouv Presse Med (1979) 0.77
Interleukin-2 therapy for refractory and relapsing lymphomas. Eur J Cancer (1991) 0.77
Cisplatin and vindesine for disseminated non-small cell lung cancer. Results of a prospective trial with 81 patients. Bull Cancer (1990) 0.77
Feasibility and preliminary results of intensive chemotherapy and extensive irradiation in selected patients with limited small-cell lung carcinoma--results of three consecutive phase II programs. Acta Oncol (2000) 0.77
MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol (1999) 0.76
Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB. J Clin Oncol (1985) 0.76
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplant (2002) 0.76
HLA-unrestricted killing of HIV-1 gag protein-expressing CD4 T cells by gag-specific CD8 cytotoxic T cells. AIDS (1999) 0.75
Complete remission following recombinant interferon alpha-2a in a patient with diffuse large B cell cutaneous lymphoma. Nouv Rev Fr Hematol (1989) 0.75
Interleukin-2 therapy with or without lymphokine-activated killer-cell infusions for low-grade non-Hodgkin's lymphomas? J Clin Oncol (1992) 0.75
Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? J Clin Oncol (1998) 0.75
Actuarial rate of clinical and biological progression in a cohort of 250 HIV-1-seropositive subjects. Laennec HIV Study Group. Clin Exp Immunol (1990) 0.75
Axillary Hodgkin's disease in manual workers. Acta Haematol (1979) 0.75
[Levamisole, stimulant of the immune system in animal and man (author's transl)]. Pathol Biol (Paris) (1977) 0.75
[Possibilities of treatment reduction in Hodgkin's disease (author's transl)]. Dtsch Med Wochenschr (1979) 0.75
Detection of anti-estradiol antibodies and of 17beta-estradiol by means of a 17beta-estradiol-bacteriophage T4 conjugate. Dependence of the haptenated phage reaction on several physical parameters. Eur J Immunol (1974) 0.75
Viroimmunoassay of prostaglandin F-2-alpha at the picogram level. Prostaglandins (1974) 0.75
Features and prognosis of chemotherapy-treated Hodgkin's disease with initial bone marrow involvement. Cancer Chemother Pharmacol (1979) 0.75
[Acute myeloblastic leukaemia in the course of non-Hodgkin's lymphoma (author's transl)]. Nouv Presse Med (1980) 0.75
[A trial of combined chemotherapy and radiotherapy for stage IV Hodgkin's disease with initial lung involvement (author's transl)]. Dtsch Med Wochenschr (1978) 0.75
[Axillary forms of Hodgkin's disease. Considerations on its etiology and clinical aspects]. Med Welt (1979) 0.75
[Sites of relapse in Hodgkin's disease with bone marrow involvement treated by multiagent-chemotherapy (author's transl)]. Bull Cancer (1978) 0.75
Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. Leuk Lymphoma (1996) 0.75
[Acute alithiasic cholecystitis caused by interleukin-2]. Presse Med (1994) 0.75
[Clinical aspects and therapy of stage III Hodgkin's disease (author's transl)]. MMW Munch Med Wochenschr (1980) 0.75
[Angioimmunoblastic lymphadenopathy treated by levamisole]. Nouv Presse Med (1979) 0.75
[Association of Epstein-Barr virus and Hodgkin's disease: comparison between Algerian and French patients]. Bull Cancer (1995) 0.75
[Hodgkin disease, clinical stages IA-IIB: evaluation of the value of cisplatin. Preliminary results]. Bull Cancer (1993) 0.75
[Brain metastasis from poorly differentiated neuroendocrine lung carcinoma. Complete response after intensive chemotherapy]. Presse Med (1992) 0.75
[Small cell lung cancers: intensive and short chemotherapy followed by irradiation. Results of a pilot study]. Presse Med (1991) 0.75
[Possibilities of radiation-dose reduction in the treatment of Hodgkin's disease. I. Exclusion of the mediastinum from the radiation field in primary high-cervical or infradiaphragmatic involvement and stage I or II (author's transl)]. Dtsch Med Wochenschr (1979) 0.75
The effect of levamisole on human chromosomes. Pathol Biol (Paris) (1980) 0.75
[Longtime complications in patients with malignant lymphomas following chemo- and (or) radiotherapy. Virus infections--leukemias--sterility]. Dtsch Med Wochenschr (1978) 0.75
Metastatic undifferentiated nasopharyngeal carcinoma (UCNT) can present as isolated cervical lymphadenopathy. Histopathology (2006) 0.75
[Transcutaneous puncture biopsy of retroperitoneal lymph nodes opacified on lymphography. 10 cases]. Nouv Presse Med (1980) 0.75
[Malignant melanoma after bilateral retinoblastoma]. Presse Med (1993) 0.75
Use of the human immunodeficiency virus virion as a universal standard for viral RNA quantitation by reverse transcription-linked polymerase chain reaction. J Infect Dis (1993) 0.75
Effect of levamisole on interferon production by PHA-stimulated human leukocyte cultures. Biomedicine (1979) 0.75
Levamisole and autoimmunity in angioimmunoblastic lymphadenopathy. Acta Haematol (1979) 0.75
[Physiological significance of prostaglandins]. Ann Med Interne (Paris) (1973) 0.75
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leuk Lymphoma (1995) 0.75
[Stage III and VI Hodgkin's disease. Success and failure of therapeutic protocol H2 65 (author's transl)]. Nouv Presse Med (1979) 0.75
[Treatment of Hodgkin's disease stages I, II, and III]. Nouv Rev Fr Hematol Blood Cells (1977) 0.75
[Treatment of angioimmunoblastic lymphadenopathy with high doses of corticoids]. Nouv Presse Med (1980) 0.75
[Initial pattern and evolution of Hodgkin's disease with pulmonary involvement (author's transl)]. Nouv Presse Med (1978) 0.75
Burkitt's lymphoma occurring 6 years after Hodgkin's disease. Acta Haematol (1980) 0.75
[An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal]. Presse Med (1997) 0.75
[Biology of small-cell bronchogenic carcinoma: recent advances]. Bull Cancer (1992) 0.75
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program]. Bull Cancer (1997) 0.75
Comparison of Epstein-Barr virus markers in Reed-Sternberg cells in adult Hodgkin's disease tissues from an industrialized and a developing country. Leuk Lymphoma (1995) 0.75